The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Benicar is an angiotensin II receptor blocker (ARB) approved for
the treatment of hypertension. This once-daily oral tablet that may
be administered alone or in combination with other antihypertensive
Hypertension, the term used for abnormally high blood pressure,
is the most common health problem in the United States. Over 50
million Americans suffer from hypertension, but many are unaware of
the problem and remain untreated. Left untreated, it can lead to
serious and life-threatening events including stroke and heart
Approval of Benicar is supported by 7 placebo-controlled
studies, with doses ranging from 2.5 to 80 mg, given for six to 12
weeks. The trials included more than 3275 subjects with essential
hypertension. All seven studies reported significant reductions in
peak and trough levels of diastolic and systolic blood pressure.
Response was dose-related, with 20 mg and 40 mg doses inducing the
desired effect and doses over 40 mg having little additional
effect. The blood pressure lowering effect from using Benicar
once-daily was maintained throughout the 24 hour period, with
trough-to-peak ratios for systolic and diastolic response between
60 and 80%.
Adverse events associated with the use of Benicar may include
(but are not limited to) the following:
Mechanism of Action
Benicar (olmesartan medoxomil) blocks the vasoconstrictive
effects of angiotensin II by selectively blocking the binding of
angiotensin II to the AT receptor in vascular smooth muscle.